《卫生经济学》课程参考文献（WHO年度报告）：World Health Report 2004 changing history

团购合买资源类别：文库，文档格式：PDF，文档页数：96，文件大小：3.76MB

changing history The World Health Report 2004 World Health Organization c h a n ging history The World H e alth R e p ort 2 0 0 4 WHO The world has reached a crucial moment in the history of HIV/AIDS, and now has an unprecedented opportunity to alter its course. The most important message of the latest World Health Report is that, today, the international community has the chance to change the history of health for generations to come and open the door to better health for all. Tackling HIV/AIDS is the world’s most urgent public health challenge. Unknown barely a quarter of a century ago, it is now the leading cause of death for young adults worldwide. More than 20 million people have died from it and an estimated 34–46 million others are now infected with the virus. There is as yet no vaccine and no cure. The World Health Report 2004 – Changing History, published by the World Health Organization, calls for a comprehensive HIV/AIDS strategy that links prevention, treatment, care and long-term support. Until now, treatment has been the most neglected element in most developing countries: almost 6 million people in these countries will die in the near future if they do not receive treatment – but only about 400 000 of them were receiving it in 2003. WHO and its partners have declared the treatment gap a global emergency and have launched a drive to provide 3 million people in developing countries with antiretroviral therapy by the end of 2005 – one of the most ambitious public health projects ever conceived. This report shows how it can be done. It goes further, looking beyond 2005 to explain how international organizations, national governments, the private sector and communities can combine their strengths and simultaneously fortify health systems for the enduring benefi t of all. Illustrated with photographs of people whose lives have been deeply affected by the global pandemic, The World Health Report 2004 makes essential reading for everyone with a political, professional or personal interest in health. ISBN 92 4 156265 X

ii iii Message from the Director-General ix Overview xi A chance to change history xii Why treatment must be scaled up xiii Expanding treatment access xiii Towards Health for All xiv Chapter summaries xv Chapter 1 A global emergency: a combined response 1 The global situation 1 The uneven spread of HIV 3 Rises in mortality, reductions in life expectancy 4 The deadly interaction: HIV/AIDS and other diseases 7 The AIDS treatment gap 7 The human, social and economic consequences 8 Women: unequally at risk 8 The underestimated economic threat 9 The threat of institutional collapse 10 Prevention, care and support: strategies for change 11 Preventing the sexual transmission of HIV 12 Breaking the link with other sexually transmitted infections 13 Preventing infection in infants and children 13 Injecting drug use – reducing the harm 15 Preventing transmission during health care 15 Testing and counselling 15 contents WHO Library Cataloguing-in-Publication Data World Health Organization. The World health report : 2004 : changing history. 1.World health - trends 2.HIV infections - therapy 3.Acquired immunodefi ciency syndrome - therapy 4.Acquired immunodefi ciency syndrome - therapy 5.Anti-retroviral agents - supply and distribution 6.Delivery of health care - organization and administration 7.World Health Organization I.Title II.Title: Changing history. ISBN 92 4 156265 X (NLM Classifi cation: WA 540.1) ISSN 1020-3311 © World Health Organization 2004 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Publications, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specifi c companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. Information concerning this publication can be obtained from: World Health Report World Health Organization 1211 Geneva 27, Switzerland E-mail: whr@who.int Copies of this publication can be ordered from: bookorders@who.int Design: Reda Sadki Layout: Steve Ewart, Sue Hobbs and Reda Sadki Printing coordination: Keith Wynn Printed in France 2004/15763 – Sadag – 20000 This report was produced under the overall direction of Tim Evans (Assistant Director-General), Robert Beaglehole (Editor-in-Chief), Jim Kim (Special Adviser to the Director-General) and Paulo Teixeira (Director, HIV/AIDS). The principal authors were Robert Beaglehole, Alec Irwin and Thomson Prentice. The other main contributors to chapters were: Chapter One: Ties Boerma, Jean-Paul Moatti, Alex de Waal and Tony Waddell. Chapter Two: Jhoney Barcarolo, Alex Capron, Charles Gilks, Alaka Singh and Marco Vitoria. Chapter Three: Hedwig Goede, Ian Grubb and Stephanie Nixon. Chapter Four: David Evans, Neelam Sekhri, Phyllida Travis and Mark Wheeler. Chapter Five: Don Berwick, Michel Kazatchkine and Yves Souteyrand. Other contributors to the report were: Christopher Bailey, Michel Beusenberg, Boakye Boatin, Andrew Boulle, Guy Carrin, David Coetzee, François Dabis, Betina Durovni, Dominique Egger, Paula Fujiwara, Claudia Garcia-Moreno, Eric Goemaere, Peter Graaf, Raj Gupta, Kate Hankins, Kei Kawabata, Wayne Koff, Michael Lederman, Ying-Ru Lo, Naisiadet Mason, Kedar Mate, J.P. Narain, Carla Obermeyer, Amolo Okero, Catherine Orrell, Andreas Reis, Peter Reiss, Alan Stone, Tessa Tantorres, Kate Taylor, Roger Teck and David Walton. Contributors to statistical tables were: Carla Abou-Zahr, Prerna Banati, Steve Begg, Christina Bernard, Ana Betran, Maureen Birmingham, Daniel Bleed, Monika Blössner, Anthony Burton, Laurent Chenet, Christopher Dye, Charu Garg, Peter Ghys, Patricia Hernández, Mehran Hosseini, Jose Hueb, Chandika Indikadahena, Mie Inoue, Peter Jackson, Doris Ma Fat, Colin Mathers, Sumi Mehta, John Miller, Bernard Nahlen, Mercedes de Onis, Richard Poe, Leonel Pontes, Jean-Pierre Poullier, Nathalie Proust, Eva Rehfuess, Kenji Shibuya, Karen Stanecki, Michel Thieren, Niels Tomijima, Nathalie Van de Maele, Catherine Watt and Hongyi Xu. Valuable input was received from Assistant Directors-General, policy advisers to the Director-General at WHO headquarters, and many technical staff. Additional help and advice were kindly provided by Regional Directors and members of their staff. The report was edited by Barbara Campanini and Leo Vita-Finzi. Translation coordination and other administrative and production support was provided by Shelagh Probst. The web site version and other electronic media were provided by Gael Kernen. The photographs and media kit were coordinated by Gary Walker. Proofreading was by Marie Fitzsimmons. The index was prepared by Kathleen Lyle

Chapter 5 Sharing research knowledge 73 Prevention research 74 Linking prevention and access to treatment 74 Preventing transmission from mother to child 76 Protecting women with microbicides 77 Vaccine research 77 Treatment research 78 Sustaining long-term adherence 78 Coping with toxicities 79 Preventing drug resistance 79 Developing new drugs and strategies 80 Tackling tuberculosis and HIV/AIDS together 80 Operational research 81 Economic issues 82 Health policy analysis 83 Equity issues 84 International collaboration 84 Sharing knowledge 86 Conclusion 91 Statistical annex 9 3 Explanatory notes 93 Annex Table 1 Basic indicators for all WHO Member States 112 Annex Table 2 Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002 120 Annex Table 3 Burden of disease in DALYs by cause, sex and mortality stratum in WHO regions, estimates for 2002 126 Annex Table 4 Healthy life expectancy (HALE) in all WHO Member States, estimates for 2002 132 Annex Table 5 Selected national health accounts indicators: measured levels of expenditure on health, 1997–2001 136 Annex Table 6 Selected national health accounts indicators: measured levels of per capita expenditure on health, 1997–2001 144 Annex Table 7 Millennium Development Goals: selected health indicators in all WHO Member States, 2000 (unless specifi ed) 148 List of Member States by WHO region and mortality stratum 156 Chapter 2 The treatment initiative 21 Treatment scale-up: public health arguments 23 Treatment scale-up: economic and social arguments 24 The 3 by 5 strategy 25 Partnerships: vital for success 26 Delivering treatment: a practical new approach 27 Antiretroviral drug resistance: acting now to prevent a major problem 29 The costs of achieving 3 by 5 30 The front lines: working in countries 32 China 32 India 33 Kenya 34 Thailand 34 Zambia 35 Ethical policies for treatment 35 Making 3 by 5 work for the poor and marginalized 36 Beyond 2005 38 Chapter 3 Community participation: advocacy action 43 Community participation in public health 44 Civil society responds to the AIDS tragedy 45 The power of a human rights approach 47 Civil society and treatment expansion 48 From advocacy to service implementation 48 Community health workers and treatment 50 Community empowerment and public health: shaping the future 52 Chapter 4 Health systems: fi nding new strength 57 Investing in change 58 Beyond the public sector 59 The business sector contribution 59 Leadership for change 61 Health information systems 61 Monitoring 3 by 5 62 Service delivery 62 Health system resources 64 The human resource crisis 64 Systemic solutions to the workforce crisis 64 Financing issues 66 Meeting the challenge: hope for the future 69 iv v

viii ix We are living in a time of unprecedented opportunities for health. In spite of many diffi culties, technology has made important advances and international investment in health has at last begun to fl ow. Most of the increased funding is for the fi ght against HIV/AIDS. It brings a welcome and long overdue improvement in the prospects for controlling the worst global epidemic in several centuries. The responsibility of WHO and its partners in this effort is to ensure that the increased funding is used in such a way as to enable countries to fi ght HIV/AIDS and at the same time strengthen their health systems. HIV/AIDS control involves the full spectrum of economic, social and technical activities. A key role of WHO within this spectrum is to work with countries to build up the systems needed to provide treatment. Expanding the use of antiretroviral therapy will allow countries to support effective systems for delivering chronic care, thus extending their capacity to meet the long-term health needs of the population. The initiative to make antiretroviral therapy available to 3 million people by the end of 2005 (known as “3 by 5”) is aimed at accelerating this process. It provides new ways to pursue the objectives for which WHO has been working since it was founded 56 years ago. However, the stakes are high: rapid expansion of antiretroviral treatment is a large, complex and diffi cult undertaking. It certainly cannot by done by one agency working on its own. Partnerships are indispensable for a task of this magnitude. Making them work requires great commitment, goodwill and talent on all sides. The initiative draws its strength from many partners with large amounts of all these ingredients, and we expect much more. But I am well aware that we and our partners took a risk in embracing 3 by 5. What I strongly felt we needed was a time-limited, diffi cult goal that would change the way we work. This is the best way to challenge ourselves to make the contribution that we as WHO should be making to the global effort against HIV/AIDS. Future generations will judge our era in large part by our response to the AIDS pandemic. By tackling it decisively we will also be building health systems that can meet the health needs of today and tomorrow, and continue the advance to Health for All. This is an historic opportunity we cannot afford to miss. LEE Jong-wook Director-General World Health Organization Geneva, May 2004 message from the director-general

xi overview The two photographs on the opposite page show how the history of HIV/AIDS is changing. They are snapshots of the past and the present, a vivid example of how, today, innovative treatment programmes are not only saving lives but also helping to strengthen health systems on which to build a brighter future. Joseph Jeune is a 26-year-old peasant farmer in Lascahobas, a small town in central Haiti. When the fi rst picture was taken in March 2003, his parents had already bought his coffi n. Suffering from the advanced stages of AIDS, Joseph Jeune probably had only weeks to live. The second picture, taken six months later, shows him 20 kg heavier and transformed after receiving treatment for HIV/AIDS and tuberculosis (TB) coinfection. There are millions of people like Joseph Jeune around the world. For most of them, HIV/AIDS treatment is still beyond reach, but Joseph shows what can be achieved. He receives care at the small clinic in his home town. The clinic’s HIV/AIDS and TB treatment programmes are part of a wider initiative to strengthen the health service infrastructure across much of Haiti’s central plateau. The effort involves nongovernmental organizations, the public sector and communities, with major support from the Global Fund to Fight AIDS, Tuberculosis and Malaria. Using antiretroviral therapy as an entry point, the programme is building up primary health care in communities, for a total population of about 260 000 people. It does so through improved drug procurement and management, the expansion of HIV counselling and testing, increased salaries for local health care personnel, and the training of numerous community health care workers. Primary care clinics have been refurbished, restocked with essential medicines, and provided with new staff. They are receiving up to 10 times more patients for general medical care daily than before the project began. The World Health Report 2004 shows how projects like this can bring the medical treatment that saved Joseph Jeune to millions of other people in poor and middle-income countries and how, crucially, such efforts can drive improvements in health systems. Effectively tackling HIV/AIDS is the world’s most urgent public health challenge. Already, the disease has killed more than 20 million people. Today, an estimated 34–46 million others are living with HIV/AIDS. In 2003, 3 million people died and 5 million others became infected. Unknown a quarter of a century ago, HIV/AIDS is now the leading cause of death and lost years of productive life for adults aged 15–59 years worldwide. David Walton/Partners in Health

xii The World Health Report 2004 overview xiii Thérapeutique Hospitalière en Réseau (ESTHER), initiated by the French government and now supported by Italy, Luxembourg, Spain and other partners. Success in expanding HIV/AIDS treatment depends on the engagement of civil society. Without the mobilization of activist organizations and communities, the toll of HIV/AIDS over the past quarter-century would have been far heavier. The momentum for antiretroviral scale-up owes much to the sustained advocacy of treatment activists at local, national and global levels and to nongovernmental organizations such as Médecins Sans Frontières and Partners In Health-Zami Lasante, which demonstrated to the world the feasibility of delivering antiretroviral treatment in the poorest settings. This report shows WHO’s commitment to work closely with national health authorities, the private sector, community-based organizations and others in delivering comprehensive HIV/AIDS programmes on the ground. WHY TREATMENT MUST BE SCALED UP The long-term economic and social costs of HIV/AIDS have been seriously underestimated in many countries. More accurate projections now suggest that some countries in sub-Saharan Africa will face economic collapse unless they can bring their epidemics under control, mainly because HIV/AIDS weakens and kills adults like Joseph Jeune in their prime. Data in this report and the forthcoming UNAIDS/WHO Global report confi rm that the social devastation of the epidemic continues to grow. Reinforced prevention is vital to safeguard future generations but, at the same time, antiretroviral treatment expansion is essential to protect the stability and security of communities, countries and regions and to strengthen the foundations of future development. The fact that effective treatment exists but has not been made accessible to millions of people in urgent need is something that WHO must tackle, given its special responsibility within the UNAIDS family of cosponsors. WHO’s Constitution charges the Organization to pursue the universal realization of the right to health: “the attainment by all peoples of the highest possible level of health”. In the case of HIV/AIDS, for those in clinical need of treatment the realization of this right requires access to antiretrovirals. EXPANDING TREATMENT ACCESS The report explains that the treatment initiative draws on the specific comparative strengths of multilateral, national and local actors and capitalizes on the motivating effect of a time-bound target. Between the declaration of the global treatment emergency in September 2003 and the end of February 2004, more than 40 of the countries with the highest burden of HIV/AIDS expressed commitment to rapid treatment expansion and requested technical cooperation in designing and implementing scale-up programmes. WHO and its partners have worked closely with country health offi cials, treatment providers, community organizations and other stakeholders to revise treatment targets, design national treatment scale-up plans and launch implementation. In countries such as Kenya, the United Republic of Tanzania, and Zambia, WHO is linking with key bilateral partners to develop a target-focused, streamlined approach that will maximize effi ciency under clear national leadership. Political commitment and national ownership of programmes are essential. The streamlined funding mechanisms developed by the Global Fund are enabling many countries to access funding and expand programmes more quickly. As new funding fl ows in, technical and human resource capacities must be ready to ensure its effective use. Countries need technical cooperation to support implementation on the ground and have requested clear guidance on treatment delivery and programme management. WHO makes a fundamental contribution by providing such guidance. A comprehensive HIV/AIDS strategy links prevention, treatment, care and support for people living with the virus. Until now, treatment has been the most neglected element in most developing countries. Yet among all possible HIV-related interventions it is treatment that can most effectively drive health systems strengthening, enabling poor countries to protect their people from a wide range of health threats. This report shows how international organizations, national governments, the private sector and communities can combine their strengths to expand access to HIV/AIDS treatment, reinforce HIV prevention and strengthen health systems in some of the countries where they are currently weakest, for the long-term benefi t of all. Almost 6 million people in developing countries will die in the near future if they do not receive treatment – but only about 400 000 of them were receiving it in 2003. In September 2003, WHO, the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the Global Fund declared lack of access to AIDS treatment with antiretroviral medicines a global health emergency. In response, these organizations and their partners launched an effort to provide 3 million people in developing countries with antiretroviral therapy by the end of 2005 – the 3 by 5 initiative, one of the most ambitious public health projects ever conceived. A CHANCE TO CHANGE HISTORY Advocacy by WHO and its partners for more global investment in health has begun to bear fruit. Offi cial development assistance and other forms of global health investment are on the rise. Most of the increased spending is for HIV/AIDS. Along with the urgent need to tackle the pandemic, this fact now makes HIV/AIDS the key battleground for global public health. It also gives countries the chance to derive extra public health benefi ts from the new funds. The opportunity exists to invest these resources so as to save millions of threatened lives through treatment, reinforce comprehensive HIV/AIDS control and strengthen some of the world’s most fragile health systems. The objective of treating 3 million people in developing countries with antiretroviral drugs by the end of 2005 is a step on the way to the goal of universal access to antiretroviral therapy and HIV/AIDS care for all who need it. This goal far outreaches the capacities of any single organization. Through collaboration linking the skills of many partners, however, these aims can be achieved. The treatment initiative is important not only to tackle a grave health crisis, but also because it is building innovative mechanisms of collaboration in health, linking national governments, international organizations, the private sector, civil society groups and communities. Success in partnership on the initiative will accelerate other areas of global health work. The initiative adapts lessons from HIV/AIDS programmes in developed countries and builds on the achievements of developing countries such as Botswana, Brazil, Senegal and Thailand in scaling up antiretroviral treatment. An increasing number of effective partnerships will mean that no country has to face the HIV/AIDS treatment challenge alone. UNAIDS has, for nearly a decade, kept HIV/AIDS at the forefront of global consciousness and spurred recognition that only an exceptional response can meet the challenge. Under its leadership, the entire United Nations system has embraced its responsibilities. The creation of the Global Fund has fostered partnership between governments, civil society, the private sector and affected communities. The World Bank has brought innovation, and is joined now by the European Union, bilateral initiatives such as the United States President’s Emergency Plan for AIDS Relief, and the major contributions of individual governments and private foundations, including the Bill and Melinda Gates Foundation and the William J. Clinton Foundation. There have also been inventive new approaches to technical cooperation, such as hospital twinnings through the Ensemble pour une Solidarité

xiv The World Health Report 2004 overview xv poor, viewing HIV/AIDS treatment expansion and the Millennium Development Goals as steps on the road to Health for All. The treatment initiative will not end in 2005. Ahead lie the challenges of extending treatment to many more millions of people and maintaining it for the rest of their lives, while simultaneously building and sustaining the health infrastructures to make that huge task possible. The ultimate aim is nothing less than to reduce health inequalities by building up effective, equitable health systems for all. CHAPTER SUMMARIES Chapter 1. A global emergency: a combined response This chapter describes the current epidemiological state of HIV/AIDS epidemics around the world and examines the daunting challenges that lie ahead. It shows that the world is far from ready for what is to come: it provides evidence that the social and economic consequences of unchecked HIV/AIDS epidemics will be catastrophic for many communities and countries. Although it has seemed a familiar enemy for much of the last 20 years, the global HIV/ AIDS pandemic is only now beginning to be seen for what it is: a unique threat to human society, whose impact will be felt by future generations. The most explosive growth of the pandemic occurred during the middle of the 1990s, especially in sub-Saharan Africa. Today, an estimated 34–46 million people are living with HIV/AIDS. Two-thirds of the total live in Africa, where about one in 12 adults is infected, and one-fi fth in Asia. Globally, unprotected sexual intercourse between men and women is the predominant mode of transmission of the virus. The chapter explains why WHO, along with its partners, believes an emergency global and comprehensive response is essential and must embrace prevention, treatment and long-term care. Prevention is essential to protect the many millions of young adults and children who are most at risk but who are not yet affected. Treatment is the difference between life and death for the millions of people who are HIV-positive but are currently denied access to antiretroviral medications. Long-term care is also essential. Almost 6 million people need treatment now – only about 400 000 received it in 2003. The chapter argues that a treatment gap of such dimensions is indefensible, and that narrowing it is a public health necessity. Together, prevention, treatment and long-term care and support can reverse the seemingly inexorable progress of the HIV/AIDS epidemics, offering the worst-affected countries and populations their best hope of survival. Chapter 2. The treatment initiative This chapter stresses the need for a comprehensive strategy that links prevention, treatment, research, and long-term care and support for people living with HIV/AIDS. But it points out that until now, treatment has been the most neglected component of this approach in much of the developing world. To accelerate prevention while limiting the social devastation now unfolding, rapid expansion of HIV/AIDS treatment with antiretroviral medicines in the countries hardest hit by the pandemic is needed immediately. Despite mounting evidence that this treatment works in resource-poor settings, by late 2003 less than 7% of people in developing countries in urgent need were receiving it. The chapter examines public health arguments and economic and social arguments for scaling up antiretroviral therapy. It then presents WHO’s strategy for working with countries and partners to reach the treatment target and provides an estimate of the global An important task is to expand as rapidly as possible from small pilot projects to treatment programmes with national coverage, while maintaining quality of care in the face of serious resource constraints. For rapid expansion, noticing gaps in resources is the starting point for a plan to redesign care so that it is, from the outset, “scalable”. The initiative takes a practical “engineering” or “system design” approach. The key is not to require that countries simply accumulate the usual resources for care – enough doctors, nurses, clinics, and so on – to reach the entire population; in many poor countries, that will just not work at present. Instead, the WHO strategy begins with clearly defi ned objectives, and then works to develop innovative system designs that can be expanded even when the usual medical resources are in very short supply. Such solutions will vary from country to country, but many factors are relatively constant, and many lessons can be shared. The strategy draws on solid evidence of the success of pioneering projects and some existing national programmes. Knowledge gained, systematically measured and refl ected upon can be quickly reapplied and shared widely. To help accelerate the initiative, WHO has developed a simplifi ed set of antiretroviral drug regimens, testing and treatment guidelines that are consistent with the highest standards of quality of care. They have the added advantage of enabling much more effective use of nurses, clinical offi cers and community health workers to support treatment. While physicians supervise the clinical teams, day-to-day patient management and adherence support tasks can be safely and effectively delegated to other workers, including appropriately trained community health workers. In this way there is a better chance of delivering care quickly despite shortages of physicians, laboratories and other facilities. These simplifi ed regimens are the critical element in ensuring that expansion of treatment in poor countries can be carried out equitably. WHO has also designed streamlined guidelines for training health workers in a wide range of skills related to the use of antiretroviral drugs, from HIV counselling and testing and recruitment of patients to treatment delivery, clinical management of patients and the monitoring of drug resistance. WHO is now working on the ground with health offi cials, treatment providers and communities to overcome technical challenges; it is also serving as a coordination, communications and information-sharing hub to gather, analyse and disseminate data, and is feeding back the information so that it can be used rapidly to improve programme performance. This intensifi ed collaboration on antiretroviral treatment scale-up is part of WHO’s broad commitment to working closely with countries to meet their major health goals. WHO, in partnership with UNICEF and the World Bank, has established the AIDS Medicines and Diagnostics Service as an operational arm to ensure that developing countries have access to quality antiretrovirals and diagnostic tools at the best prices. The service aims to help countries to buy, forecast and manage the supply and delivery of products necessary for the treatment and monitoring of HIV/AIDS. As policy and technical support work at country level intensifi es, WHO, UNAIDS and their partners will continue their global advocacy work to ensure that adequate resources fl ow to support countries. New resources available through the Global Fund and other partners will be critical to success. On request, WHO is providing countries with technical assistance in the preparation of applications to the Global Fund and other potential funders. TOWARDS HEALTH FOR ALL The global HIV/AIDS treatment gap refl ects wider patterns of inequality in health and is a test of the international community’s commitment to tackle these inequalities. Beyond working to save millions of lives under immediate threat, WHO and its partners are confronting a broad range of health problems that affl ict poor communities and keep them

xvi The World Health Report 2004 overview xvii investment required. It explains the fi ve pillars that support the strategy. These are: global leadership, strong partnership and advocacy; urgent, sustained country support; simpli- fi ed, standardized tools for delivering antiretroviral therapy; effective, reliable supply of medicines and diagnostics; and rapid identifi cation and reapplication of new knowledge and successes. The opportunities and challenges facing selected countries are explored, highlighting the need to ensure that treatment scale-up reaches the poorest people. Finally, the chapter considers the wider importance of expanded treatment as a new way of working across the global health community for improved health outcomes and equity. Chapter 3. Community participation: advocacy and action The participation of communities and civil society groups, particularly groups of people living with HIV/AIDS, is crucial to treatment scale-up and comprehensive HIV/AIDS control. This participation will include both advocacy and the involvement of community members in delivering services and support to patients. Community involvement is essential to prevention, treatment, care, support and research. This chapter describes the background of community participation as a dimension of public health work and recalls key achievements of civil society HIV/AIDS activism. It then considers the roles that civil society groups and community members will play in scaling up antiretroviral therapy in resource-poor settings. State leadership will be indispensable to successful scale-up, and civil society cannot replace the public sector. But a key task of effective government leadership will be creating partnerships with civil society organizations and mechanisms to make use of the skills available within communities. The commitment to community participation links the treatment strategy with the Health-for-All vision and an equity-based agenda in global public health. The values of human rights, health equity and social justice embraced by many civil society AIDS activist groups are closely related to WHO’s constitutional objective: “the attainment by all peoples of the highest possible level of health”. This chapter shows that these values provide a basis for ongoing collaboration and partnerships between communities, civil society groups, national governments and international organizations, including WHO. Such collaboration will be crucial to future health progress. The role of the 3 by 5 initiative in catalysing innovative partnerships is part of how it is changing ways of thinking and working in global health. For example, communities educated and mobilized around HIV/AIDS control will be better able to take part in health promotion, disease control and treatment efforts regarding health problems related to other Millennium Development Goals: to combat malaria and other diseases, maternal and child mortality, and the growing burden of chronic adult diseases in low-income and middle-income countries. Chapter 4. Health systems: fi nding new strength Health sector interventions against HIV/AIDS – especially the treatment initiative – are dependent on well-functioning health systems. In countries with a high burden of HIV/AIDS, systems are often degraded and dysfunctional because of a combination of underfunding and weak governance. HIV/AIDS places additional burdens on these weakened health systems. The 3 by 5 initiative has the potential to strengthen health systems in a number of ways, by, for example, attracting resources to the health system in addition to those required for HIV/AIDS, stimulating investment in physical infrastructure, developing procurement and distribution systems of generic application, and fostering interaction with communities which can benefi t a wide range of health interventions. It is important that any potentially adverse effects on the wider health system are anticipated and minimized. The chapter continues with a consideration of the health systems context in resourcepoor settings, taking note of the participation of both public and private providers. It then considers how health systems can be strengthened, so that they can implement the expanded treatment initiative while continuing to improve and expand many other health interventions. The conceptual framework of the four main functions of health systems is used: leadership, service delivery, resource provision, and fi nancing. In the medium term, the fi nancing gap will have to be closed mainly by external donors, because national governments and economies are incapable of generating much more than they do already, whereas donors, aware of their past pledges, can be enouraged to do more. Chapter 5. Sharing research and knowledge This chapter records that, since scientists fi rst identifi ed the human immunodefi ciency virus as the cause of AIDS in 1983, there have been many remarkable research achievements related to the disease and many people have benefi ted. Twenty years ago there was little effective treatment; today there is a range of antiretroviral drugs that dramatically improve patients’ quality of life and chances of survival. Despite signifi cant advances, however, including the design and testing of more than 30 candidate HIV vaccines, it will be several more years at least before a safe and effective vaccine becomes widely available. In examining that continuing quest, the chapter also reviews research into other important areas of HIV/AIDS prevention, treatment and care. There are four broad categories of challenges facing researchers. ■ Prevention research – slowing down the growth and geographical expansion of the epidemic: a challenge for epidemiology and sociobehavioural aspects of prevention. ■ Vaccine research – designing a safe and effective preventive vaccine, the best hope for the long-term prevention and control of HIV/AIDS. ■ Treatment research – generating new antiretroviral drugs and designing new therapeutic strategies that would be active on “wild” and resistant strains of viruses, easy to take and better tolerated than currently available drugs: a challenge for basic and clinical research. ■ Delivery system (operational) research – making care and antiretroviral treatment available to all of those who need it worldwide: a multidisciplinary undertaking. The chapter examines important matters such as the prevention of HIV transmission from mother to child; the development and use of microbicides; the need to sustain long-term adherence to treatment; toxicities; drug resistance; joint approaches to HIV/AIDS and tuberculosis; economic issues; health policy analysis; equity issues; and international collaboration. The chapter leads on to the report’s brief concluding section, which contains an optimistic view of the future. It emphasizes that a crucial moment has been reached in the history of HIV/AIDS, and that there is now an unprecedented opportunity to alter its course. Ahead lies the challenge of extending lifelong treatment to many more millions of people, while simultaneously building and sustaining the health infrastructures to make that huge task possible. The outcome can be better health for generations to come

点击进入文档下载页（PDF格式）

共96页，可试读20页，点击继续阅读 ↓↓

点击下载（PDF格式）

浏览记录